PHARMA PLUS
Sources: the KBO register on 19-11-2026; the National Bank, 2025 annual accounts filed on 12-05-2026; the Belgian Official Gazette, latest deed of 04-08-2026.
Grounds
the facts the verdict rests on, each with its source- In 2025, PHARMA PLUS closed with a net profit of €15,884.Annual accounts 2025 page 2
- Equity stands at €876,038, or 85.2% of the balance sheet total of €1.0m. That is more than 59% of the 2,455 companies in the retail trade sector (NACE 47).Annual accounts 2025 page 2
- The last five annual accounts came in on time. The 2025 accounts were filed 80 days before the end of the term.National Bank, filing of 12-05-2026 page 5
- (0405.366.364) holds all the shares. Its equity stood at €33.0m on 31-12-2025. That parent has 34 holdings.Annual accounts 2025 of page 4
Representation
Checked did not find the signing rule in the deeds it read.
Ownership
(0405.366.364) holds all the shares. Its equity stood at €33.0m on 31-12-2025.
Annual accounts 2025 of
Financial situation
Annual accounts 2021 to 2025, as filed with the National Bank
Gross margin and net resultin €m
Equity and debtsin €m
Cashin €m
| Financial year | 2021 | 2022 | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|---|---|
| Results | ||||||
| Gross margin | €436,803 | €483,482 | €453,821 | €602,949 | €248,353 | |
| Operating result | €75,885 | €125,879 | €70,529 | €95,214 | €12,076 | |
| Net result | €54,870 | €92,689 | €50,938 | €78,352 | €15,884 | |
| Balance sheet at the closing date | ||||||
| Equity | €1.0m | €1.1m | €781,803 | €860,154 | €876,038 | |
| Debts | €190,287 | €226,450 | €296,324 | €189,118 | €152,303 | |
| Debts due within one year | €190,287 | €226,450 | €296,324 | €189,118 | €152,303 | |
| Cash | €6,981 | €13,408 | €11,810 | €5,478 | €5,375 | |
| Balance sheet total | €1.2m | €1.3m | €1.1m | €1.0m | €1.0m | |
| Operations | ||||||
| Employees in full-time equivalents | 6.5 | 5.6 | 5.9 | 4.2 | 4.1 | |
| Ratios | ||||||
| Solvency | 84.1% | 82.9% | 72.5% | 82.0% | 85.2% | |
| Liquidity | 2.98 | 3.31 | 1.86 | 4.31 | 5.13 | |
Source: Annual accounts 2025, full format, filed on 12-05-2026 (2026-00111137); Annual accounts 2024, full format, filed on 17-06-2025 (2025-00144634); Annual accounts 2021 to 2023, filed from 07-06-2022 to 12-06-2024 (2022-20051853, 2023-00123324, 2024-00127224).
The operating result of 2025 is 87% lower than in 2024.
Debts fell by €36,815 in 2025.
The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.
Board, signature and ownership
Position on 19-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
Checked did not find the signing rule in the deeds it read.
Board
four directors in officealso sits on the boards of 45 other companies. also sits on the boards of 31 other companies. also sits on the boards of 3 other companies.
Ownership and group
Shareholders
(0405.366.364) holds all the shares. Its equity stood at €33.0m on 31-12-2025.
Annual accounts 2025 of
Board changes
resigns. appointed. acts as permanent representative. General meeting of 19-05-2026.
Gazette, deed 26099510New chair of the board. appointed, resigned. and act as permanent representatives. Board meeting of 01-09-2022.
Gazette, deed 22147566Issue of 17,000 shares. changes role from director to managing director. appointed as chair. General meeting of 22-12-2020.
Gazette, deed 21037955resigns as managing director. and (managing director) appointed. acts as permanent representative. General meeting of 29-02-2016.
Gazette, deed 16038448(managing director and chair of the board) and (director) reappointed. General meeting of 22-04-2011.
Gazette, deed 11186793Group
has 34 holdings (2025 accounts).
| Country | Company | Year | Equity | Result | |
|---|---|---|---|---|---|
| Belgium 34 | |||||
| BE | PHARMA PLUSthis company | 2025 | €876,038 | result €15,884 | |
| BE | 2025 | €2.0m | result €70,063 | ||
| BE | 2025 | €2.0m | result €70,773 | ||
| BE | 2025 | €1.8m | result €27,487 | ||
| BE | 2025 | €1.5m | result €39,635 | ||
| BE | 2025 | €1.3m | result €31,345 | ||
| BE | 2025 | €1.2m | result -€21,813 | ||
| BE | 2025 | €1.2m | result €68,611 | ||
| BE | 2025 | €1.2m | result €6,589 | ||
| BE | 2025 | €1.2m | result -€87,206 | ||
| BE | 2025 | €1.2m | result €52,938 | ||
| BE | 2025 | €1.1m | result €49,219 | ||
| BE | 2025 | €1.1m | result €74,220 | ||
| BE | 2025 | €913,124 | result €83,390 | ||
| BE | 2025 | €908,418 | result €66,552 | ||
| BE | 2025 | €875,529 | result €21,018 | ||
| BE | 2025 | €619,306 | result €28,974 | ||
| BE | 2025 | €573,958 | result €56,725 | ||
| BE | 2025 | €556,284 | result €35,837 | ||
| BE | 2025 | €538,245 | result €40,263 | ||
| BE | 2025 | €485,489 | result €51,818 | ||
| BE | 2025 | €483,944 | result €67,222 | ||
| BE | 2025 | €463,825 | result €46,725 | ||
| BE | 2025 | €437,140 | result €23,964 | ||
| BE | 2025 | €426,866 | result €31,577 | ||
| BE | 2025 | €368,033 | result €15,209 | ||
| BE | 2025 | €358,217 | result €26,706 | ||
| BE | 2025 | €351,857 | result €43,562 | ||
| BE | 2025 | €331,470 | result -€22,880 | ||
| BE | dissolved | 2026 | €265,436 | result -€829 | |
The dossier shows 4 more holdings.
Source: List of holdings in the 2025 accounts of . Every holding stands with its own latest accounts.
Events and comparison
The last 24 months, newest first
resigns. appointed. acts as permanent representative. General meeting of 19-05-2026.
Gazette, deed 26099510Annual accounts 2025 filed, 80 days before the deadline.
NBB filingAnnual accounts 2024 filed, 44 days before the deadline.
NBB filingRegistered in the Peppol Directory. Reachable for e-invoices through 0208:0432850028.
Liquidity more than doubled. The current ratio rises from 1.86 to 4.31. Short-term debt falls from €296,324 to €189,118.
FinancialComparable companies, two years later
In July 2024, 17,047 companies had the same profile as PHARMA PLUS has now: micro, 20 years or older, solvency 30% or more and a profit under 5% of the balance sheet. Two years later 94.3% were still trading, 5.2% had stopped another way and 0.5% had gone bankrupt.
In 2025, PHARMA PLUS had a lower net result than 66% of the 2,456 companies in the retail trade sector (NACE 47).
Other findings
Peppol
Reachable for e-invoices since 06-06-2025, under 0208:0432850028.
Sanctions lists
Staff
5 employees on 31-12-2025, 4.1 full-time equivalents on average over the year.
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 19-11-2026 | KBO 0432.850.028 |
| National Bank of Belgium | Annual accounts 2025, full format | 12-05-2026 | 2026-00111137 |
| National Bank of Belgium | Annual accounts 2024, full format | 17-06-2025 | 2025-00144634 |
| National Bank of Belgium | Annual accounts 2021 to 2023 | 07-06-2022 to 12-06-2024 | 2022-20051853, 2023-00123324, 2024-00127224 |
| Belgian Official Gazette | Board | 04-08-2026 | deed 26099510 |
| Belgian Official Gazette | Board | 14-12-2022 | deed 22147566 |
| Belgian Official Gazette | Board | 25-03-2021 | deed 21037955 |
| Peppol Directory | Registration for e-invoices | 06-06-2025 | 0208:0432850028 |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 16-11-2026 | no match |
| Checked | Checked score, bankruptcy probability, credit, comparable companies | 18-11-2026 | bankruptcy model of 2 October 2026 |
Method
Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 18-11-2026.
Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.
Payment terms. Supplier credit is the debt to suppliers divided by the year's purchases, times 365. Customer credit is the same for what customers still owe, against turnover.
Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.
The scores and ratios are Checked's own calculations, not a credit decision.